GARP Research

GARP Research & Securities was an independent equity research firm that specialized in providing in-depth analysis of small-cap and mid-cap stocks, with a primary focus on the healthcare, biotechnology, and life sciences sectors. The firm was well-known for its detailed coverage of emerging medical technologies and drug development pipelines, serving institutional clients such as mutual funds, pension funds, and hedge funds. Its analysts, often possessing advanced scientific backgrounds, provided critical insights into the commercial potential of complex biotech innovations. While the firm was highly influential in the 2000s and early 2010s, it eventually transitioned its operations, with its founder later establishing Gaineswood Investment Management. GARP Research is frequently cited in historical biotech financial literature for its early and accurate assessments of companies like Illumina and Myriad Genetics.